

## Biliary Cirrhosis

[View the current Biliary Cirrhosis InDepth page on BioPortfolio.com \(PDF\)](#)

([http://www.bioportfolio.com/indepth/Biliary\\_Cirrhosis.html](http://www.bioportfolio.com/indepth/Biliary_Cirrhosis.html)) - Regularly Updated.

### Recent Publications on Biliary Cirrhosis:



- [Fatigue measurements in patients with primary biliary cirrhosis and the risk of mortality during follow-up.](#)  
*Background: Fatigue was recently suggested to predict an increased risk of...* 20th November, 2009  
Department of Internal Medicine, Section of Gastroenterology and- Liver Int. 2009 Nov 17. ([DOI Direct Link](#))
- [Extrahepatic conditions associated with primary biliary cirrhosis.](#)  
*Background: Fatigue was recently suggested to predict an increased risk of...* 18th November, 2009  
Hepatogastroenterology Department, Hospital Universitario de La Princesa,- Hepatology. 2009 Aug 10. ([DOI Direct Link](#))
- [Hepatic pseudolymphoma: a clinicopathological study of five cases and review of the literature.](#)  
*Hepatic pseudolymphoma is a rare and controversial condition, the...* 17th November, 2009  
[1] Institute of Liver Studies, King's College Hospital, London, UK [2]- Mod Pathol. 2009 Nov 13. ([DOI Direct Link](#))
- [CX3CL1 \(fractalkine\): A signpost for biliary inflammation in primary biliary cirrhosis.](#)  
*Improvements in the treatment of primary biliary cirrhosis (PBC) may...* 13th November, 2009  
Department of Medicine and Biosystemic Science, Kyushu University Graduate- Hepatology. 2009 Nov 11. ([DOI Direct Link](#))
- [\[Primary biliary cirrhosis\]](#)  
*In the Netherlands there are probably several thousands of patients with...* 11th November, 2009  
Erasmus MC, afd. Maag-, Darm- en Leverziekten, Rotterdam, The Netherlands.- Ned Tijdschr Geneeskd. 2009;153:A483.
- [Surveillance and screening of primary sclerosing cholangitis.](#)  
*Primary sclerosing cholangitis (PSC) represents an idiopathic chronic...* 10th November, 2009  
Gastroenterology and Hepatology Department, Essen University Hospital,- Dig Dis. 2009;27(4):526-35. Epub 2009 Nov 4. ([DOI Direct Link](#))
- [Bone Mineral Density and Serum Levels of Soluble Tumor Necrosis Factors, Estradiol, and Osteoprotegerin in Postmenopausal Women with Cirrhosis after Viral Hepatitis.](#)  
*Context: Cirrhosis after viral hepatitis has been identified as a risk...* 10th November, 2009  
Department of Gastroenterology (J.L.G.-C., J.L.M., F.J.C.-C., A.C.A.,- J Clin Endocrinol Metab. 2009 Nov 6. ([DOI Direct Link](#))
- [A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis.](#)  
*In primary biliary cirrhosis (PBC) serum markers other than...* 10th November, 2009  
Center for Autoimmune Diseases Sheba Medical Center, Israel; Department of- J Autoimmun. 2009 Nov 6. ([DOI Direct Link](#))

- [Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease.](#)  
*BACKGROUND & AIMS: The management of non-alcoholic liver disease (NAFLD)...*10th November, 2009  
UK NIHR Biomedical Research Centre in Ageing - Liver Theme, Newcastle- J Hepatol. 2009 Oct 23. ([DOI Direct Link](#))
- [Autoimmune Hepatitis-PBC Overlap Syndrome: A Simplified Scoring System May Assist in the Diagnosis.](#)  
*OBJECTIVES:Primary biliary cirrhosis (PBC) with features consistent with...*6th November, 2009  
Department of Internal Medicine, Section of Gastroenterology and- Am J Gastroenterol. 2009 Nov 3. ([DOI Direct Link](#))
- [\[Primary biliary cirrhosis: therapeutic options\]](#)  
*Primary biliary cirrhosis (PBC) is a chronic and slowly progressive...*5th November, 2009  
Unita Operativa Fisiopatologia Digestiva, Dipartimento di Medicina- Recenti Prog Med. 2009 Sep;100(9):417-23.
- [Bezafibrate Treatment of Primary Biliary Cirrhosis Following Incomplete Response to Ursodeoxycholic Acid.](#)  
*BACKGROUND AND GOALS: Ursodeoxycholic acid (UDCA) is the only current...*3rd November, 2009  
Department of Medicine D, Liver Institute, Rabin Medical Center Beilinson- J Clin Gastroenterol. 2009 Oct 29. ([DOI Direct Link](#))
- [Characterisation of the activated liver progenitor cell niche, potential involvement of Wnt and Notch signalling.](#)  
*BACKGROUND: Hepatic progenitor cells (HPCs) hold a great potential for...*3rd November, 2009  
Belgium;- Gut. 2009 Nov 1. ([DOI Direct Link](#))
- [B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice.](#)  
*The treatment of primary biliary cirrhosis (PBC) with conventional...*31st October, 2009  
Division of Rheumatology, Allergy and Clinical Immunology, University of- Hepatology. 2009 Aug 10. ([DOI Direct Link](#))
- [Toward the molecular dissection of primary biliary cirrhosis.](#)  
*The treatment of primary biliary cirrhosis (PBC) with conventional...*31st October, 2009  
- Hepatology. 2009 Nov;50(5):1347-50. ([DOI Direct Link](#))

## BioNews Results for Biliary Cirrhosis

- [Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis](#)  
*Individual.com: Oct 28 2009 1:43AM Matching: biliary cirrhosis*

## Biliary Cirrhosis Patents:

- 7585507- [Nucleic acid molecules and polypeptides for immune modulation](#)



- 7595311- [Azepinoindole derivatives as pharmaceutical agents](#)
- 7595318- [Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids](#)
- 7595341- [Analogues of lipid mediators derived from .omega.-3 PUFAs and methods of use](#)
- 7597886- [Tumor necrosis factor-gamma](#)
- 7597907- [Antioxidant polymer nanocarriers for use in preventing oxidative injury](#)
- 7598067- [PDEs and uses thereof](#)
- 7598280- [Heterocyclic compounds, compositions comprising them and methods of their use](#)
- 7598289- [Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions](#)
- 7598348- [Adiponectin receptor variant, AdipoR2v2](#)
- 7601335- [Pretreatment of a biological sample from an autoimmune disease subject](#)
- 7595192- [Process for the production of temperature-induced tumor cell lysates for use as immunogenic compounds](#)
- 7595038- [Methods of treatment using antibodies to follistatin-3](#)
- 7592422- [Modified plasminogen activator inhibitor type-1 and methods based thereon](#)
- 7585883- [Substituted pyridines and their uses](#)
- 7588776- [Pharmaceutical use of water-soluble fraction of Graptopetalum](#)
- 7588930- [Compositions and methods for enhancing the immunogenicity of antigens](#)
- 7589087- [Benzoimidazol-2-yl pyridines as modulators of the histamine H.sub.4receptor](#)
- 7589091- [Hydroxamic acid derivatives](#)
- 7591994- [Camptothecin-binding moiety conjugates](#)
- 7592007- [Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies](#)
- 7592010- [Albumin fusion proteins](#)
- 7592147- [Modulation of IL-2 production by T-bet](#)
- 7592326- [Method for stimulating the immune, inflammatory or neuroprotective response](#)
- 7601349- [GIPs, a family of polypeptides with transcription factor activity that interact with Goodpasture antigen binding protein](#)
- 7601514- [Nucleic acid encoding PRO10268 polypeptides](#)
- 7612064- [Sulfofyrroles](#)
- 7612180- [Humanized L243 antibodies](#)
- 7612181- [Dual variable domain immunoglobulin and uses thereof](#)
- 7612182- [Anti-IL-6 antibodies, compositions, methods and uses](#)
- 7615380- [Methods for modulating an immune response by modulating KRC activity](#)
- 7615535- [Inhibiting GS-FDH to modulate no bioactivity](#)
- 7615552- [Fused heterocyclic compounds](#)
- 7615562- [2-aminopyrimidine derivatives and their medical use](#)
- 7618629- [Manipulation of cytokine levels using CD83 gene products](#)
- 7618632- [Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies](#)
- 7611879- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor](#)
- 7611851- [Canis sphingosine 1-phosphate receptor isoform 1](#)
- 7611708- [Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies](#)
- 7601713- [Kinase inhibitors and their uses](#)
- 7601843- [4-\(2-furoyl\)aminopiperidine compound useful as therapeutic agent for itching](#)
- 7604797- [Compositions and methods for treating burns](#)
- 7604800- [Anti-PSGL-1 antibodies](#)
- 7605171- [\(3,4-disubstituted\)propanoic carboxylates as S1P \(Edg\) receptor agonists](#)
- 7605229- [PRO87299 polypeptides](#)
- 7605236- [Antibodies that immunospecifically bind to B lymphocyte stimulator protein](#)
- 7608392- [Diagnostic assay for measuring a cell mediated immune response](#)
- 7608430- [Interferon-gamma. antagonists and therapeutic uses thereof](#)
- 7608683- [Stress proteins and peptides and methods of use thereof](#)
- 7618646- [Matrix, cell implant and method for their production and use](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

